Delisting of Calliditas Therapeutics AB (publ) from Nasdaq Stockholm

Rhea-AI Summary

Calliditas Therapeutics AB (publ) is set to be delisted from Nasdaq Stockholm. The stock exchange has made the decision, with the final trading day scheduled for Thursday, October 10, 2024. This significant development was announced on September 16, 2024, at 15:30 CET. For investors and stakeholders seeking more information, Åsa Hillsten, the Head of IR & Sustainability at Calliditas, has been designated as the contact person.

Positive

• None.

Negative

• Delisting from Nasdaq Stockholm
• Last trading day on October 10, 2024

Insights

Financial Analyst

The delisting of Calliditas Therapeutics from Nasdaq Stockholm is a significant development for investors. This move typically signals a major change in the company's strategy or ownership structure. Delisting can impact liquidity and valuation of the stock, potentially making it harder for existing shareholders to trade their shares.

Investors should be aware that after delisting, the company may have reduced reporting requirements, potentially limiting transparency. It's important to understand the reasons behind this decision, which could include a private buyout, merger, or financial restructuring. The short notice period (24 days) suggests a rapid transition, which may indicate underlying urgency or a pre-planned strategic move.

Shareholders should closely monitor any forthcoming announcements regarding potential buyout offers or alternative trading arrangements post-delisting.

Market Research Analyst

The delisting of Calliditas Therapeutics from Nasdaq Stockholm could have broader implications for the Swedish biotech sector. This move might reflect challenges in the local market for maintaining public listings, especially for specialized pharmaceutical companies.

Investors should consider whether this is part of a larger trend or an isolated incident. If it's the former, it could signal a shift in the landscape for biotech investments in Sweden, potentially leading to more companies seeking alternative funding sources or international listings.

The timing of this announcement, coming just before the end of the year, may also be strategic, possibly aligning with fiscal year-end considerations or regulatory timelines. It's worth watching for any ripple effects on similar companies in the Nordic biotech ecosystem.

STOCKHOLM, Sept. 16, 2024 /PRNewswire/ -- Nasdaq Stockholm has decided that Calliditas Therapeutics AB (publ) will be delisted from Nasdaq Stockholm. The last day of trading in the share will be on Thursday, October 10, 2024.

For further information, please contact:

Åsa Hillsten, Head of IR & Sustainability, Calliditas

Tel.: +46 76 403 35 43, Email: asa.hillsten@calliditas.com

The information was sent for publication, through the agency of the contact person set out above, on September 16, 2024 at 15:30 CET.

About Calliditas

Calliditas Therapeutics is a biopharma company headquartered in Stockholm, Sweden, focused on identifying, developing, and commercializing novel treatments in orphan indications with significant unmet medical needs. Calliditas' common shares are listed on Nasdaq Stockholm (ticker: CALTX). Visit Calliditas.com for further information.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/calliditas-therapeutics/r/delisting-of-calliditas-therapeutics-ab--publ--from-nasdaq-stockholm,c4038098

The following files are available for download:

https://mb.cision.com/Main/16574/4038098/3002835.pdf

Calliditas- announcing date for de-listing (eng)

View original content:https://www.prnewswire.com/news-releases/delisting-of-calliditas-therapeutics-ab-publ-from-nasdaq-stockholm-302249090.html

SOURCE Calliditas Therapeutics

FAQ

When will Calliditas Therapeutics (CALT) be delisted from Nasdaq Stockholm?

Calliditas Therapeutics (CALT) will be delisted from Nasdaq Stockholm on October 10, 2024, which is the last day of trading for the stock on this exchange.

What is the reason for Calliditas Therapeutics (CALT) being delisted from Nasdaq Stockholm?

The press release does not provide a specific reason for the delisting of Calliditas Therapeutics (CALT) from Nasdaq Stockholm. It only states that Nasdaq Stockholm has made the decision to delist the company.

Who should investors contact for more information about Calliditas Therapeutics (CALT) delisting?

Investors can contact Åsa Hillsten, Head of IR & Sustainability at Calliditas, for more information about the delisting. She can be reached at +46 76 403 35 43 or asa.hillsten@calliditas.com.

What are the implications for shareholders of Calliditas Therapeutics (CALT) after the delisting?

The press release doesn't provide specific information about the implications for shareholders. Typically, delisting can affect stock liquidity and trading options. Shareholders should contact the company or their financial advisors for guidance.